NIH R01 · 2024
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity
PROJECT SUMMARY/ABSTRACT Immunotherapies that boost anti-tumor T cells are landmark breakthroughs in oncology. Yet, current immunotherapies directly activate T cells and are therefore ineffective in ~80% of tumors with few T cells (“cold” tumors). Thus, a primary challenge in oncology is to develop effective immunotherapies for cold tumors. Pancreatic ductal adenocarcinoma (PDAC) is a prime example – ~91% of tumors have few T cells, and thus PDAC rarely responds to current immunotherapies (<2% response rate). Yet, immunotherapy is the most promising option in PDAC, as all other therapies have failed, and only the rare (9%) patients with immunogenic “hot” tumors (high density of intratumoral…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.